Literature DB >> 12721793

Tissue distribution of the Ankara strain of vaccinia virus (MVA) after mucosal or systemic administration.

J C Ramirez1, D Finke, M Esteban, J P Kraehenbuhl, H Acha-Orbea.   

Abstract

MVA is a candidate vector for vaccination against pathogens and tumors. Little is known about its behaviour in mucosal tissues. We have investigated the fate and biosafety of MVA, when inoculated by different routes in C57BL/6 mice. Intranasal inoculation targeted the virus to the nasal associated lymphoid tissue and the lungs, whereas systemic inoculation led to distribution of MVA in almost all lymphoid organs, lungs and ovaries. Intravaginal, intrarectal and intragastric inoculations failed to induce efficient infection. After 48 h no virus was detectable any more in the organs analyzed. Upon intranasal inoculation, no inflammatory reactions were detected in the central nervous system as well as the upper and lower airways. These results show the tropism of MVA and indicate that high doses of recombinant MVA are safe when nasally administered, a vaccination route known to elicit strong cellular and humoral immune responses in the female genital tract.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12721793     DOI: 10.1007/s00705-003-0006-z

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  19 in total

1.  The Virulence of Different Vaccinia Virus Strains Is Directly Proportional to Their Ability To Downmodulate Specific Cell-Mediated Immune Compartments In Vivo.

Authors:  Lorena F D de Freitas; Rafael P Oliveira; Mariana C G Miranda; Raíssa P Rocha; Edel F Barbosa-Stancioli; Ana Maria C Faria; Flávio G da Fonseca
Journal:  J Virol       Date:  2019-03-05       Impact factor: 5.103

2.  A comparative analysis of HIV-specific mucosal/systemic T cell immunity and avidity following rDNA/rFPV and poxvirus-poxvirus prime boost immunisations.

Authors:  Charani Ranasinghe; Fiona Eyers; John Stambas; David B Boyle; Ian A Ramshaw; Alistair J Ramsay
Journal:  Vaccine       Date:  2011-02-23       Impact factor: 3.641

3.  Immunization with modified vaccinia virus Ankara prevents eczema vaccinatum in a murine model of atopic dermatitis.

Authors:  Michiko K Oyoshi; James Y T Wang; Raif S Geha
Journal:  J Allergy Clin Immunol       Date:  2011-08-06       Impact factor: 10.793

Review 4.  Smallpox vaccines: targets of protective immunity.

Authors:  Bernard Moss
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

5.  The Perennial Use of the Green Fluorescent Protein Marker in a Live Vaccinia Virus Ankara Recombinant Platform Shows No Acute Adverse Effects in Mice.

Authors:  D S O Daian E Silva; T M G Pinho; M A Rachid; D F Barbosa-Stancioli; F G Da Fonseca
Journal:  Braz J Microbiol       Date:  2019-03-15       Impact factor: 2.476

6.  Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge.

Authors:  Linda S Wyatt; Patricia L Earl; Leigh Anne Eller; Bernard Moss
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-11       Impact factor: 11.205

7.  Correlation of immunogenicities and in vitro expression levels of recombinant modified vaccinia virus Ankara HIV vaccines.

Authors:  Linda S Wyatt; Patricia L Earl; Jennifer Vogt; Leigh Anne Eller; Dev Chandran; Jinyan Liu; Harriet L Robinson; Bernard Moss
Journal:  Vaccine       Date:  2007-12-03       Impact factor: 3.641

8.  Aerosol immunization with NYVAC and MVA vectored vaccines is safe, simple, and immunogenic.

Authors:  Max Corbett; Willy M Bogers; Jonathan L Heeney; Stefan Gerber; Christian Genin; Arnaud Didierlaurent; Herman Oostermeijer; Rob Dubbes; Gerco Braskamp; Stéphanie Lerondel; Carmen E Gomez; Mariano Esteban; Ralf Wagner; Ivanella Kondova; Petra Mooij; Sunita Balla-Jhagjhoorsingh; Niels Beenhakker; Gerrit Koopman; Sjoerd van der Burg; Jean-Pierre Kraehenbuhl; Alain Le Pape
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-11       Impact factor: 11.205

9.  Non-equilibrium and differential function between intraepithelial and lamina propria virus-specific TCRalphabeta(+) CD8alphabeta(+) T cells in the small intestinal mucosa.

Authors:  D Isakov; A Dzutsev; I M Belyakov; J A Berzofsky
Journal:  Mucosal Immunol       Date:  2009-07-01       Impact factor: 7.313

10.  Prime-boost immunization schedules based on influenza virus and vaccinia virus vectors potentiate cellular immune responses against human immunodeficiency virus Env protein systemically and in the genitorectal draining lymph nodes.

Authors:  M Magdalena Gherardi; José Luis Nájera; Eva Pérez-Jiménez; Susana Guerra; Adolfo García-Sastre; Mariano Esteban
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.